MaxSimil is a novel, patented delivery platform that enhances the absorption of lipid-based and lipid-soluble nutraceuticals. MaxSimil mimics the human digestive process to deliver absorption-ready, pre-digested lipid-based products such as omega-3 fish oils.
MaxSimil technology provides an effective and promising delivery method to enhance absorption of omega-3 from fish oils.
A Phase I clinical study subject to Health Canada approval was conducted to assess the comparative bioavailability of a fish oil and a MaxSimil pre-digested version. Twenty healthy subjects (10 males, 10 females) were chosen according to a well-defined set of prerequisites, and were subject to a double-blind, randomized, cross-over comparative pharmacokinetic study.
Statistically significant results indicated that the EPA & DHA from MaxSimil fish oils were absorbed 3 times better than those from the regular fish oils.